Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Cancer Center, Mayo Clinic discusses a study on two adjuvant trials in patients with stage III colon cancer.
Sinicrope and his team conducted the study in order to look at the association of overall survival with colon cancers that have deficient DNA mismatch repair. Both large adjuvant trials were randomized, and they were conducted within the United States and Europe.
Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Cancer Center, Mayo Clinic discusses a study on two adjuvant trials in patients with stage III colon cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More